- Visibility18
- Citations0
- Sentiment50
- Site quality80
- AI readiness29
AI assistants name Kymera Therapeutics in 11.7% of answers, more often than the typical company in its sector. Its overall score is 32 out of 100, ranking 1,044th of 2,047 companies. The website passes 4 out of 14 technical checks for readiness with AI tools.
We asked 15 unbranded questions about the healthcare market: none named Kymera Therapeutics. AI assistants named it in 7 of 60 answers (11.7%). The typical healthcare company is named in 3.3% of answers. By how often it is named, Kymera Therapeutics ranks 20 of 105 in its sector.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“Who is a candidate for targeted protein degradation medications in immunology?”
Targeted protein degradation (TPD) medications in immunology are a promising area of research and development, offering a new approach to treating diseases by eliminating disease-causing proteins rather than just inhibiting their function. This approach has the potential to address "undruggable" targets that conventional small-molecule inhibitors cannot reach.
Candidates for targeted protein degradation medications in immunology include individuals with:
Cancer, particularly in the context of cancer immunotherapy. TPD can help reprogram the tumor microenvironment to make it more resp …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 25 of 100 · 97% of checks could run · checked on October 5, 2026 · www.kymeratx.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as US-listed.
- Who is a candidate for targeted protein degradation medications in immunology?
- What are common side effects of protein degradation therapies for hard-to-treat diseases?
- How does targeted protein degradation compare to monoclonal antibodies in immunology?
- Which non-protein degradation therapies are showing promise for difficult-to-treat illnesses?
- What are the best protein degradation therapies for autoimmune disease treatment?
- Is investing in protein degradation medicines for rare immune diseases worthwhile?
- What new developments exist in the field of protein degrading medicines for immunology?
- Are next-generation protein degrading therapies covered by major U.S. insurance providers?
- What are alternatives to targeted protein degradation in treating chronic autoimmune conditions?
- Are there financial assistance programs for patients seeking protein degradation treatment?
- Protein degradation vs traditional small molecule inhibitors—what’s the difference in mechanism and outcome?
- What is the typical cost range for advanced protein degradation therapies in the United States?
- What should patients do if they don’t respond to protein degradation treatments?
- How do protein degraders expand options for patients with refractory diseases?
- How effective is targeted protein degradation for immune-mediated conditions?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.
A badge of this result that you can show on your own website. Copy the code below.
<a href="https://aeo-audit.rezolve.com/us/kymeratx.com"><img src="https://aeo-audit.rezolve.com/us/badges/kymeratx.com.svg" alt="Overall score 32 of 100, US AI Visibility Study 2026" width="280" height="64"></a>